What is IMRX's current stock price?

IMRX (Immuneering Corporation) is currently trading at $5.39 with a market cap of $195.7M.

What sector is Immuneering Corporation in?

Immuneering Corporation (IMRX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IMRX a good stock to buy?

Analysts have a Buy consensus on IMRX with a price target of $12.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IMRX Immuneering Corporation

Healthcare

$5.39+3.26%ClosedMarket Cap: $195.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.00

P/S

0.00

EV/EBITDA

737.34

DCF Value

$2.80

FCF Yield

-25.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-0.1%

ROA

-0.0%

ROIC

-0.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-13.5M	$—
Q4 null	$0.00	$-11.6M	$—
FY null	$0.00	$-56.0M	$—
Q3 null	$0.00	$-15.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$12.00

Target (Median)

$12.00

Target Range

$12.00 - $12.00

2 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Chardan CapitalBuy

2026-05-19

NeedhamBuy

2026-03-09

Chardan CapitalBuy

2025-11-13

HC Wainwright & Co.Buy

2025-09-30

Chardan CapitalBuy

2025-09-26

Trading Activity

Insider Trades

View All

Neufeld Leah Rofficer: CHIEF PEOPLE OFFICER

SellTue Mar 17

Zeskind Benjamin J.director, officer: PRESIDENT AND CEO

SellThu Feb 05

Neufeld Leah Rofficer: CHIEF PEOPLE OFFICER

SellThu Feb 05

Morales Malloryofficer: SVP Finance, CAO

SellThu Feb 05

Matushansky Igorofficer: Chief Medical Officer

SellThu Feb 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.36

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Peers